Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

被引：1
|
作者：
Barnes, Jeffrey A.
Feng, Yang
Hochberg, Ephraim P.
Takvorian, Tak
Weitzman, James
Fisher, David C.
Jacobsen, Eric D.
Joyce, Robin
Neuberg, Donna S.
Abramson, Jeremy S.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3062.3062
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3062
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] How we treat mature B-cell neoplasms (indolent B-cell lymphomas)
    Melissa Lumish
    Lorenzo Falchi
    Brandon S. Imber
    Michael Scordo
    Gottfried von Keudell
    Erel Joffe
    Journal of Hematology & Oncology, 14
  • [42] Is there need for radioimmunotherapy? Results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab
    Forrer, F.
    Oechslin-Oberholzer, C.
    Campana, B.
    Maecke, H. R.
    Mueller-Brand, J.
    Lohri, A.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 56 (06): : 544 - 550
  • [43] Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Badoux, Xavier
    Estrov, Zeev
    Schlette, Ellen
    Smith, Susan C.
    Ayala, Ana B.
    Falchi, Lorenzo
    Calin, Steliana
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2011, 118 (21) : 780 - 780
  • [44] Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study
    Ollila, Thomas A.
    Butera, James
    Egan, Pamela C.
    Reagan, John L.
    Thomas, Anthony G.
    Yakirevich, Inna
    MacKinnon, Kelsey
    Margolis, Jeannine
    Rosati, Valerie
    McMahon, Jessica
    Robison, Jordan
    Olszewski, Adam J.
    BLOOD, 2020, 136
  • [45] Gene therapy for B cell lymphomas
    Fielding, A
    Russell, SJ
    CANCER SURVEYS, 1997, 30 : 327 - 342
  • [46] HISTOPATHOLOGIC SUBTYPES OF INDOLENT LYMPHOMAS - CARICATURES OF THE MATURE B-CELL SYSTEM
    JAFFE, ES
    RAFFELD, M
    MEDEIROS, LJ
    SEMINARS IN ONCOLOGY, 1993, 20 (05) : 3 - 30
  • [47] Antisense therapy for B cell lymphomas
    Cotter, FE
    CANCER SURVEYS, 1997, 30 : 311 - 325
  • [48] Clinical applications of circulating tumor DNA in indolent B-cell lymphomas
    Lakhotia, Rahul
    Roschewski, Mark
    SEMINARS IN HEMATOLOGY, 2023, 60 (03) : 164 - 172
  • [49] Systemic rituximab in the treatment of indolent primary cutaneous B-cell lymphomas
    Muniesa, C.
    Domingo, E.
    Fornons, R.
    Penate, Y.
    Estrach, T.
    Ramon, D.
    Medina, S.
    Florez, A.
    Ortiz, P.
    Sanchez, P.
    Torres, I.
    Acebo, E.
    Yanguas, I.
    Fernandez de Misa, R.
    Blanes, M.
    Zayas, A.
    Descalzo, M. A.
    Garcia-Doval, I.
    Servitje, O.
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S36 - S36
  • [50] Interim results of a phase II trial of therapy with cyclophosphamide/pentostatin/rituximab for indolent NHL and CLL.
    Odaimi, M
    Rubin, A
    Ahern, K
    Lee, R
    Basile, M
    Terjanian, T
    Forte, F
    McGinn, T
    Burton, JD
    BLOOD, 2002, 100 (11) : 313B - 313B
12345